Pharmacovigilance and Safety Reporting Requirements for Clinical Trials – Part 7
As Chinese biotech sponsors expand clinical trials into Europe, effective pharmacovigilance (PV) and safety reporting are essential to protect patient safety and maintain regulatory compliance. The EU has a well-established framework for clinical trial safety monitoring, including obligations under Clinical Trial Regulation (EU) 536/2014 and mandatory reporting to relevant EU and EEA authorities via EudraVigilance. Sponsors must ensure that adverse events, serious adverse events, and suspected unexpected serious adverse reactions (SUSARs) are captured, assessed, and reported in accordance with EU regulations.
Establishing a Robust Pharmacovigilance System
A compliant pharmacovigilance system begins with clear roles and responsibilities across the sponsor organization, CROs, and clinical sites. Investigators must be trained to identify, document, and report adverse events promptly. Sponsors are responsible for collecting safety data from all trial sites, assessing causality, seriousness and expectedness (per approved reference safety information), and ensuring timely reporting to regulatory authorities. Centralized databases and validated electronic systems support efficient collection, management, and analysis of safety data, reducing the risk of delayed or incomplete reporting.
EudraVigilance Reporting Requirements
EudraVigilance serves as the EU central database for adverse event reporting. Sponsors are required to submit serious adverse reactions and SUSARs within strict timelines, typically within 7 or 15 days depending on seriousness criteria. Accurate and timely reporting to EudraVigilance is critical to maintain compliance, and ensure trial participant safety across EU Member States. Multi-regional trials require additional coordination to ensure that data collected outside the EU is integrated and assessed according to EU requirements.
Clinical Trial Information System (CTIS) Safety Reporting
In addition to EudraVigilance, safety reporting via the CTIS is also required for EU clinical trials. The annual Development Safety Update Report (DSUR) must be uploaded to CTIS within 60 days of the data lock point for the reporting period. Also, if any unexpected events which affect the benefit-risk balance of the clinical trial but are not SUSARs are identified, these must be uploaded to CTIS no later than 15 days from sponsor awareness. CTIS should be monitored regularly for requests for information from EU Regulatory Authorities.
Operationalizing Safety Reporting Across Sites
For multinational trials, operational complexity arises from different site capabilities, local reporting procedures, and language requirements. Sponsors must implement standardized reporting forms, workflows, and escalation processes to ensure consistent documentation and timely submission. Site training, periodic monitoring visits, and audits help maintain high-quality data capture and ensure adherence to pharmacovigilance obligations. Integration with data management, clinical operations, and medical monitoring teams is essential to maintain a complete and accurate safety profile throughout the trial lifecycle.
End-to-End Clinical Trial Safety Compliance and Strategic Benefits
Beyond regulatory compliance, an effective pharmacovigilance system provides operational and strategic advantages. Real-time safety monitoring supports proactive risk management, improves investigator confidence, and helps maintain trial participant trust. For Chinese biotech sponsors, integrating pharmacovigilance into global trial operations ensures that EU regulatory requirements are met while facilitating timely decision-making for study continuation, amendments, or participant safety interventions. Proactive PV planning reduces the risk of regulatory queries, delays in trial progression, and potential data integrity issues.
Conclusion
Pharmacovigilance and safety reporting are integral to the success of clinical trials in Europe. By establishing a robust end-to-end clinical trial system, training investigators, leveraging centralized databases, and ensuring timely EudraVigilance and CTIS reporting, sponsors can protect trial participants, maintain regulatory compliance, and support smooth multi-regional trial execution. For Chinese biotech companies expanding into the EU, a strong pharmacovigilance framework transforms regulatory obligations into operational confidence and strategic advantage.
Previous Blog: IMP Release and Supply Management: Ensuring Compliance from Manufacture to Site
Final Blog: Country-Specific Differences and Local Strategies: Adapting to Europe’s Diverse Landscape – Caidya®